References
- Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344-55
- Catherino WH, Parrott E, Segars J. Proceedings from the National Institute of Child Health and Human Development conference on the Uterine Fibroid Research Update Workshop. Fertil Steril 2011;95:9-12
- Maruo T, Ohara N, Wang J, et al. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004;10:207-20
- D’Aloisio AA, Baird DD, DeRoo LA, et al. Early-life exposures and early-onset uterine leiomyomata in black women in the Sister Study. Environ Health Perspect 2012;120:406-12
- Lumbiganon P, Rugpao S, Phandhu-fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case–control study. Br J Obstet Gynaecol 1996;103:909-14
- Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996;41:483-90
- Coyne K, Soliman AM, Margolis MK, Castelli-Haley J, et al. Impact of uterine fibroid symptoms on health-related quality of life in a cross-sectional sample of US women. Curr Med Res Opin 2017. doi: 10.1080/03007995.2017.1372107. [Epub ahead of print]
- Borah BJ, Nicholson WK, Bradley L, et al. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol 2013;209:319
- Weidner K, Siedentopf F, Zimmermann K, et al. Which gynecological and obstetric patients want to attend psychosomatic services? J Psychosom Obstet Gynecol 2008;29:280-9
- Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016;22:665-86
- Donnez J, Schrurs B, Gillerot S, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989;51:947-50
- Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307
- Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20
- Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32
- Murji A, Whitaker L, Chow TL, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017;4:CD010770
- Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165-73
- Biglia N, Carinelli S, Maiorana A, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 2014;8:285-92
- Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206:211
- Fuldeore M, Yang H, Soliman AM, et al. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis Curr Med Res Opin 2015;31:1719-31
- Wechter ME, Stewart EA, Myers ER, et al. Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol 2011;205:492